A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.
Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR.
Macmillan ML, et al. Among authors: blazar br.
Blood. 2007 Mar 15;109(6):2657-62. doi: 10.1182/blood-2006-08-013995. Epub 2006 Nov 16.
Blood. 2007.
PMID: 17110457
Free article.
Clinical Trial.